2-amino-2-isopropyl-3-methylbutanoic acid | 98487-10-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-amino-2-isopropyl-3-methylbutanoic acid
• 英文别名: 2-amino-2-isopropyl-3-methyl-butyric acid；2-Amino-2-isopropyl-3-methyl-buttersaeure；Amino-diisopropyl-essigsaeure；3-Amino-2.4-dimethyl-pentan-carbonsaeure-(3)；alpha,alpha-Diisopropylglycine；2-amino-3-methyl-2-propan-2-ylbutanoic acid
• CAS: 98487-10-6
• 化学式: C₈H₁₇NO₂
• 分子量: 159.228
• InChiKey: OUBVKSUTYWBLCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-amino-2-isopropyl-3-methylbutanoic acid 、 异氰酸苯酯 生成 2-isopropyl-3-methyl-2-(N'-phenyl-ureido)-butyric acid
  参考文献：
  名称：

  Lin; Li; Huang, Science and technology in China, 1948, vol. 1, p. 5,9

  摘要：

  DOI：
• 作为产物：
  描述：

  2-amino-2-isopropyl-3-methyl-butyric acid methyl ester 在 盐酸 作用下， 生成 2-amino-2-isopropyl-3-methylbutanoic acid
  参考文献：
  名称：

  Lin; Li; Huang, Science and technology in China, 1948, vol. 1, p. 9

  摘要：

  DOI：

文献信息

• Method and compositions for identifying anti-HIV therapeutic compounds
  申请人：GILEAD SCIENCES, INC.

  公开号：US20040121316A1

  公开（公告）日：2004-06-24

  Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.

  提供了一种鉴定含有羧酸酯或磷酸酯基团抗HIV治疗化合物的方法。可以选择使用新型酶GS-7340酯水解酶筛选这类化合物的文库。还提供了与GS-7340酯水解酶相关的组合物和方法。
• Novel compounds and methods for synthesis and therapy
  申请人：——

  公开号：US20040053999A1

  公开（公告）日：2004-03-18

  Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

  描述了新化合物。这些化合物通常包括一个酸性基团，一个碱性基团，一个取代氨基或N-酰基和一个具有可选择羟基化的烷基部分的基团。还描述了包括本发明的抑制剂的药物组合物。还描述了在疑似含有神经氨酸酶的样品中抑制神经氨酸酶的方法。还描述了抗原材料、聚合物、抗体、本发明化合物与标记物的结合物以及用于检测神经氨酸酶活性的测定方法。
• Nitrile-containing enzyme inhibitors and ruthenium complexes thereof
  申请人：The Ohio State University Research Foundation

  公开号：US20140100173A1

  公开（公告）日：2014-04-10

  The invention provides nitrile-containing protease inhibitors caged to ruthenium compounds. The nitrile-caged ruthenium compounds provide inactivated inhibitors that can be delivered to surface or site for activation, for example, but exposure to light. The invention also provides methods for delivering protease inhibitors to subjects for the therapeutic treatment of conditions such as cancer.

  这项发明提供了与钌化合物结合的含腈基蛋白酶抑制剂。这些腈基蛋白酶抑制剂与钌化合物结合后形成失活的抑制剂，可以通过光照等方式被释放到表面或部位进行激活。该发明还提供了将蛋白酶抑制剂传递给受试者以治疗癌症等疾病的方法。
• Synthesis of α-Amino Acids via Asymmetric Phase Transfer-Catalyzed Alkylation of Achiral Nickel(II) Complexes of Glycine-Derived Schiff Bases
  作者：Yuri N. Belokon、Natalia B. Bespalova、Tatiana D. Churkina、Ivana Císařová、Marina G. Ezernitskaya、Syuzanna R. Harutyunyan、Radim Hrdina、Henri B. Kagan、Pavel Kočovský、Konstantin A. Kochetkov、Oleg V. Larionov、Konstantin A. Lyssenko、Michael North、Miroslav Polášek、Alexander S. Peregudov、Vladimir V. Prisyazhnyuk、Štěpán Vyskočil

  DOI：10.1021/ja035465e

  日期：2003.10.1

  halides, carried out under the PTC conditions in the presence of 10% mol of (S)- or (R)-2-hydroxy-2'-amino-1,1'-binaphthyl 31a (NOBIN) and/or its N-acyl derivatives and by (S)- or (R)-2-hydroxy-8'-amino-1,1'-binaphthyl 32a (iso-NOBIN) and its N-acyl derivatives, respectively, gave rise to alpha-amino acids with high enantioselectivities (90-98.5% ee) in good-to-excellent chemical yields at room temperature

  非手性、抗磁性 Ni(II) 配合物 1 和 3 由 Ni(II) 盐和席夫碱合成，分别由甘氨酸和 PBP (7) 和 PBA (11) 在 MeONa/MeOH 溶液中生成。必要的羰基衍生剂吡啶-2-羧酸（2-苯甲酰基-苯基）-酰胺 7（PBP）和吡啶-2-羧酸（2-甲酰基-苯基）-酰胺 11（PBA）很容易从吡啶甲酸中制备。酸和邻氨基二苯甲酮或吡啶甲酸和邻氨基苯甲酸甲酯，分别。1 的结构是通过 X 射线晶体学确定的。发现配合物 1 和 3 在 PTC 条件下，在 β-萘酚或苄基三乙基溴化铵作为催化剂存在下，与卤代烷进行 C-烷基化，分别得到单-和双-烷基化产物。在温和条件下用 HCl 水溶液分解复合物，得到所需的氨基酸，并回收 PBP 和 PBA。在 PTC 条件下，在 10% mol (S)-或 (R)-2-hydroxy-2'-amino-1,1'-binaphthyl 31a (NOBIN
• Blood cell deficiency treatment method
  申请人：——

  公开号：US20030083231A1

  公开（公告）日：2003-05-01

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  该发明涉及使用化合物治疗多种疾病，如血小板减少症、中性粒细胞减少症或放疗延迟效应。可以用于该发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-3β-基)-β-D-葡糖吡喃糖醛酸酯、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烷-5-烯、3,7,16,17-四羟基雄烷-4-烯、3,7,16,17-四羟基雄烷-1-烯或3,7,16,17-四羟基雄烷可用于治疗方法中。